ROCK2 and cholangiocarcinoma: The EdU assay results corroborated these findings; ROCK2-knockdown lead to a decrease in Pemigatinib-treated drug-resistant CCA cell proliferation; the addition of DFO restored the proliferative ability of these cells (Fig. 3E–H).